Deciphering the efficacy of posttransplant cyclophosphamide in haplo transplant

解读移植后环磷酰胺在单倍体移植中的功效

• 批准号: 9344023
• 负责人: Christopher Kanakry
• 金额: $ 85.32万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9344023
• 关键词: Allogeneic Bone Marrow Transplantation; Biology; Bone Marrow Transplantation; Clinical; Cyclophosphamide; Engraftment; Ensure; Goals; HLA Antigens; Human; Immunologics; Major Histocompatibility Complex; Modeling; Patients; Relapse; Translating; Transplantation; Weight; base; clinical efficacy; conditioning; graft vs host disease; improved; mouse model; prevent

We are developing an MHC-haploidentical allogeneic bone marrow transplantation model that parallels human treatment and can be used to decipher the immunologic impact of post-transplantation cyclophosphamide (PTCy). We are studying the impact of this therapy on clinical endpoints (survival, graft-versus-host disease, weight); accompanying these studies is a detailed characterization of the immunologic and histopathologic changes associated with this approach. Once the model is fully characterized and the mechanisms by which PTCy prevents GVHD uncovered, we will use this understanding as a basis to explore how to refine this BMT approach clinically towards the clinical goals of further reducing graft-versus-host disease, ensuring reliable engraftment with minimal conditioning, and serving as a platform for other therapies to reduce relapse.

我们正在开发一种mhc -单倍体相同的同种异体骨髓移植模型，该模型与人类治疗相似，可用于破译移植后环磷酰胺（PTCy）的免疫影响。我们正在研究这种疗法对临床终点（生存、移植物抗宿主病、体重）的影响；伴随这些研究的是与该方法相关的免疫学和组织病理学变化的详细描述。一旦该模型被充分表征，PTCy预防GVHD的机制被揭示，我们将以此为基础，探索如何在临床中完善这种BMT方法，以进一步减少移植物抗宿主病的临床目标，确保在最小条件下可靠的移植，并作为其他治疗减少复发的平台。